Abbas Hussain Sells 504 Shares of Moderna (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) Director Abbas Hussain sold 504 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $27.60, for a total value of $13,910.40. Following the completion of the transaction, the director owned 1,515 shares of the company’s stock, valued at $41,814. This trade represents a 24.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Moderna Trading Down 0.6%

Shares of MRNA opened at $29.46 on Friday. The business’s 50-day moving average price is $26.04 and its 200 day moving average price is $27.05. The stock has a market capitalization of $11.51 billion, a P/E ratio of -3.65 and a beta of 1.11. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $48.92.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($2.15) by $1.64. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The business’s revenue for the quarter was down 45.4% on a year-over-year basis. During the same period last year, the company posted $0.03 earnings per share. On average, research analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Monday, October 20th. Citigroup decreased their target price on Moderna from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Thursday, October 23rd. UBS Group reiterated a “buy” rating on shares of Moderna in a report on Friday, November 21st. Royal Bank Of Canada reduced their price objective on Moderna from $28.00 to $25.00 and set a “sector perform” rating for the company in a research note on Friday, November 21st. Finally, Morgan Stanley decreased their price objective on Moderna from $30.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday. Two analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $29.21.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Parkside Financial Bank & Trust raised its stake in shares of Moderna by 19.0% during the 2nd quarter. Parkside Financial Bank & Trust now owns 2,347 shares of the company’s stock worth $65,000 after purchasing an additional 375 shares in the last quarter. Probity Advisors Inc. increased its holdings in Moderna by 2.6% in the second quarter. Probity Advisors Inc. now owns 14,892 shares of the company’s stock worth $411,000 after buying an additional 377 shares during the last quarter. Amalgamated Bank raised its position in Moderna by 0.6% during the second quarter. Amalgamated Bank now owns 65,458 shares of the company’s stock valued at $1,806,000 after acquiring an additional 408 shares in the last quarter. Rothschild Investment LLC raised its position in Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after acquiring an additional 446 shares in the last quarter. Finally, Kentucky Retirement Systems Insurance Trust Fund lifted its stake in Moderna by 6.2% in the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 9,334 shares of the company’s stock valued at $241,000 after acquiring an additional 546 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.